Cytokinetics Enters Its First Year as a Commercial Company
Dec. 19, 2025 was the day Cytokinetics stopped being a clinical-stage company. The FDA’s clearance of aficamten that afternoon ended a 27-year run during which the Brisbane, California biotech had watched an ALS program fail, seen its heart failure drug … Read More